How many insider trades does FilingIQ track for VYNE?

FilingIQ tracks 152 Form 4 insider transactions for VYNE (VYNE Therapeutics Inc.), covering filings from Sep 8, 2020 onwards. 4 of those were filed in the last 90 days.

Are VYNE insiders net buyers or net sellers?

Across the full Form 4 history for VYNE, 12 transactions (8%) were open-market purchases and 4 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does VYNE insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is VYNE in?

VYNE Therapeutics Inc. (VYNE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $20.53M.

VYNE insider trading

NasdaqCM Healthcare

VYNE Therapeutics Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

152

Last 90 days

Buys / sells

8% / 3%

Market cap

$20.53M

About VYNE Therapeutics Inc.

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.

Company website: vynetherapeutics.com

VYNE insider activity at a glance

FilingIQ has scored 152 insider transactions for VYNE since Sep 8, 2020. The most recent filing in our index is dated Mar 31, 2026.

Across the full history, 12 open-market purchases and 4 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on VYNE insider trades is 59.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live VYNE trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for VYNE?: FilingIQ tracks 152 Form 4 insider transactions for VYNE (VYNE Therapeutics Inc.), covering filings from Sep 8, 2020 onwards. 4 of those were filed in the last 90 days.
Are VYNE insiders net buyers or net sellers?: Across the full Form 4 history for VYNE, 12 transactions (8%) were open-market purchases and 4 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does VYNE insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is VYNE in?: VYNE Therapeutics Inc. (VYNE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $20.53M.

Methodology & sources

Every VYNE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.